{
  "eval_id": "S23",
  "timestamp": "2025-09-19T09:03:08.220723+00:00",
  "model": "gpt-4o",
  "temperature": 0.6,
  "rep_input": "Patient HR+/HER2- progressed after CDK4/6; what key label-based caveats should I discuss?",
  "model_output": "For a patient with HR+/HER2- breast cancer who has progressed after CDK4/6 inhibitors, it's crucial to consider the specific options available on the label. Focus on the patient's performance status, any visceral involvement, and their overall goals of therapy. Please email me the SmPC or EPAR for the specific drug you're referring to, and I'll review it for any additional label-based considerations."
}